Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's experimental drug to treat ...

Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV specialist ViiV Healthcare in a deal that ...

The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...

FM6SS and GSK Maroc signed a strategic partnership for biomedical research, therapeutic innovation, and medical practices across Morocco.

GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics ...

GSK Velu reappointed as Chairman of FICCI Tamil Nadu State Council for 2025-2026, emphasizing healthcare innovation and ...

In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of ...

Under the terms of the agreement, GSK will pay RAPT Therapeutics shareholders $58.00 per share at closing for an estimated ...

GSK has agreed to buy a pharmaceutical firm that is developing treatment for people with food allergies in a deal valued at 2 ...

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.

Pfizer in ​December had warned that the next few years would be bumpy, ‌beginning with 2026, ‍due to lower sales of its COVID ...